Giuseppe Curigliano has been appointed as the President Elect of ESMO

The European Society for Medical Oncology (ESMO) has announced the results of its presidential election. Giuseppe Curigliano, MD, PhD, Director of the Early Drug Development Division and Co-chair of the Experimental Therapeutics Program at the European Institute of Oncology in Milan, will serve as the ESMO President for the 2027-2028 term.

“ESMO should lead the way in decoding cancer complexity to prevent and cure cancer through science and education, transforming patient and survivor outcomes beyond geographical boundaries,” said Curigliano. “As ESMO President, my mission will be to overcome current challenges in integrating diverse oncology disciplines through a comprehensive plan focused on education and inclusivity towards global progress in cancer care.”

About Giuseppe Curigliano

Giuseppe Curigliano, MD, PhD, is the Director of the Early Drug Development Division and co-chairs the Experimental Therapeutics Program at the European Institute of Oncology. He is a member of the Department of Oncology and Hemato-Oncology’s steering committee at the University of Milan and serves on the Italian National Health Council, advising the Ministry of Health on cancer policy issues.

Dr. Curigliano has international experience, having worked at Columbia University’s Comprehensive Cancer Center in New York and as a visiting scholar at the Dana-Farber Cancer Institute, Harvard Medical School in Boston. He co-directed the Division of Medical Oncology at the European Institute of Oncology until 2014.

Within the European Society for Medical Oncology (ESMO), he has held several key roles, including Chair of the ESMO Nomination Committee (2018-2021) and Chair of the ESMO Clinical Practice Guidelines Committee (2020-2023). He was instrumental in founding the ESMO Breast Cancer Congress and helped launch the ESMO Living Guidelines and the Fellow of ESMO (FESMO) recognition. Additionally, he has organized and participated in numerous professional and educational programs for oncologists worldwide.

Recognized as one of the world’s most influential researchers by Clarivate™️ in 2022 and 2023, Professor Curigliano serves on the editorial boards of several international oncology journals, including the European Journal of Oncology, Journal of Clinical Oncology, and Annals of Oncology. He is currently the Editor-in-Chief of ESMO Open.

Friends and colleagues also congratulated Giuseppe Curigliano on his new position.

Quoting Vivek Subiah’s, Chief of Early-Phase Drug Development at Sarah Cannon Research Institute post:

“Huge congratulations to the amazing Giuseppe Curigliano for being elected as ESMO President for 2027-28! Great colleague, friend, visionary, mentor for the next generation, inspires and leads by example.”

Source: Vivek Subiah/X

Quoting Chandler Park’s, Professor at the University of Louisville School of Medicine, post:

“Outstanding news!

Congratulations to Dr. Giuseppe Curigliano as our new ESMO President-elect. Our ESMO community is in GREAT hands with Dr. Giuseppe Curigliano.”

Source: Chandler Park/X

Quoting Paolo Tarantino’s, Research Fellow at Dana-Farber Cancer Institute and Harvard Medical School, post:

“Terrific news for ESMO and for oncology: Giuseppe Curigliano will be the ESMO President 2027-2028!

Can’t wait to see his experience, energy, and passion drive further expansion in the impact of ESMO, at the benefit of patients, physicians, and all stakeholders.

Congrats Giuseppe Curigliano!”

Source: Paolo Tarantino/X

Quoting Bishal Gyawali’s, Associate Professor at Queen’s University, post:

“Many congratulations, Giuseppe. I’m sure ESMO will reach greater heights as a global organization under your leadership. Looking forward to working together to improve outcomes for our patients globally!”

Source: Bishal Gyawali/X

Quoting Yüksel Ürün’s, Medical Oncology professor at Ankara University School of Medicine, post:

“Congratulations to Giuseppe Curigliano!

Excited to see your leadership. Wishing you great success in advancing global cancer care!”

Source: Yüksel Ürün/X

Our team at OncoDaily extends congratulations to Dr. Giuseppe Curigliano on this deserving election.